Viral Envelope Proteins

• 

  Subject Areas on Research

  • A collaborative framework for 3D alignment and classification of heterogeneous subvolumes in cryo-electron tomography. 
  • A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. 
  • A laboratory-adapted HCV JFH-1 strain is sensitive to neutralization and can gradually escape under the selection pressure of neutralizing human plasma. 
  • A novel imaging method for quantitative Golgi localization reveals differential intra-Golgi trafficking of secretory cargoes. 
  • A retroviral-derived peptide phosphorylates protein kinase D/protein kinase Cmu involving phospholipase C and protein kinase C. 
  • A synthetic peptide homologous to retroviral envelope protein down-regulates TNF-alpha and IFN-gamma mRNA expression. 
  • A synthetic peptide homologous to retroviral transmembrane envelope proteins depresses protein kinase C mediated lymphocyte proliferation and directly inactivated protein kinase C: a potential mechanism for immunosuppression. 
  • A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1. 
  • Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. 
  • Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteins. 
  • Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. 
  • Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells. 
  • Anti-idiotypic antibodies as vaccine candidates. The immune network. 
  • Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection. 
  • Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. 
  • Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection. 
  • Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. 
  • Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. 
  • Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. 
  • Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. 
  • Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate. 
  • Antiinflammatory effects of neoplasms. 
  • Antiinflammatory proteins associated with human and murine neoplasms. 
  • Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. 
  • Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein. 
  • Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. 
  • C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2. 
  • CD4 receptor diversity in chimpanzees protects against SIV infection. 
  • Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. 
  • Cell biology. Propelling progeny. 
  • Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. 
  • Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. 
  • Cellular immune response to viral peptides in patients exposed to HIV. 
  • Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. 
  • Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. 
  • Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. 
  • Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. 
  • Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C HIV-1 isolate in rhesus macaques. 
  • Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques. 
  • Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. 
  • Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. 
  • Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. 
  • Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. 
  • Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. 
  • Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). 
  • Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state. 
  • Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III). 
  • Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus. 
  • Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. 
  • Determination of molecular structures of HIV envelope glycoproteins using cryo-electron tomography and automated sub-tomogram averaging. 
  • Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection. 
  • Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. 
  • Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein. 
  • Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 
  • Effective antibody therapy in herpes simplex virus ocular infection. Characterization of recipient immune response. 
  • Effects of tumor growth on host defenses. 
  • Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif. 
  • Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. 
  • Enhanced duck hepatitis B virus gene expression following aflatoxin B1 exposure. 
  • Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice. 
  • Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1) pathogenesis. 
  • Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. 
  • Evolution of relative synonymous codon usage in Human Immunodeficiency Virus type-1. 
  • Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. 
  • Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. 
  • Functional analysis of the transcription control region located within the avian retroviral long terminal repeat. 
  • GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? 
  • GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. 
  • Glycoprotein B of human herpesvirus 8 is a component of the virion in a cleaved form composed of amino- and carboxyl-terminal fragments. 
  • Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. 
  • HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. 
  • HIV antibodies for treatment of HIV infection. 
  • HIV vaccine rationale, design and testing. 
  • HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? 
  • HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. 
  • HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. 
  • High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques. 
  • Human IFN-gamma production is inhibited by a synthetic peptide homologous to retroviral envelope protein. 
  • Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. 
  • Human T-cell leukemia/lymphoma virus: studies of host-virus interaction. 
  • Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. 
  • Human malignant and mitogen-transformed cells contain retroviral P15E-related antigen. 
  • Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation. 
  • Humoral Immune Correlates for Prevention of Postnatal Cytomegalovirus Acquisition. 
  • Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. 
  • Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. 
  • Immunobiology of the HIV envelope. 
  • Immunobiology of the human immunodeficiency virus envelope and its relationship to vaccine strategies. 
  • Immunodominant sites of human T cell lymphotropic virus type 1 envelope protein for murine helper T cells. 
  • Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. 
  • Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. 
  • In vivo genetic variability of the human immunodeficiency virus type 2 V3 region. 
  • Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. 
  • Induction of intracellular cAMP by a synthetic retroviral envelope peptide: a possible mechanism of immunopathogenesis in retroviral infections. 
  • Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. 
  • Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. 
  • Inhibition of interleukin-2 and interferon-gamma by an HIV-1 Nef-encoded synthetic peptide. 
  • Inhibition of lymphocyte proliferation by a synthetic peptide homologous to envelope proteins of human and animal retroviruses. 
  • Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. 
  • Inhibition of murine cytotoxic T lymphocyte activity by a synthetic retroviral peptide and abrogation of this activity by IL. 
  • Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. 
  • Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization. 
  • Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees. 
  • Involvement of an ATP-dependent peptide chaperone in cross-presentation after DNA immunization. 
  • Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. 
  • Isolation and initial characterization of the BRCA2 promoter. 
  • Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys. 
  • Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. 
  • Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeys. 
  • Location and role of free cysteinyl residues in the Sindbis virus E1 and E2 glycoproteins. 
  • Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. 
  • Membrane protein structure determination using cryo-electron tomography and 3D image averaging. 
  • Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. 
  • Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage. 
  • Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. 
  • Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome. 
  • Murine malignant cells synthesize a 19,000-dalton protein that is physicochemically and antigenically related to the immunosuppressive retroviral protein, P15E. 
  • Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. 
  • Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. 
  • Nucleotide sequence of the envelope protein genes of a highly virulent, neurotropic strain of Newcastle disease virus. 
  • Oral Coadministration of an Intramuscular DNA/Modified Vaccinia Ankara Vaccine for Simian Immunodeficiency Virus Is Associated with Better Control of Infection in Orally Exposed Infant Macaques. 
  • Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. 
  • Phenotypic properties of transmitted founder HIV-1. 
  • Phosphorylation of DHBV pre-S: identification of the major site of phosphorylation and effects of mutations on the virus life cycle. 
  • Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. 
  • Prevention of herpes keratitis by monoclonal antibodies specific for discontinuous and continuous epitopes on glycoprotein D. 
  • Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. 
  • Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. 
  • Progress in HIV-1 vaccine development. 
  • Properties of mouse leukemia viruses. XVII. Factors required for successful treatment of spontaneous AKR leukemia by antibodies against gp71. 
  • Properties of mouse leukemia viruses: XX. Variation of AKR Substrains in response to antibody therapy. 
  • Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. 
  • Prospects for prevention of and early intervention against HIV. 
  • Proteins of purified Epstein-Barr virus. 
  • Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. 
  • Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. 
  • Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. 
  • Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. 
  • Retroviral protein P15E and tumorigenesis. Expression is neither required nor sufficient for tumor development. 
  • Role of antibodies to murine leukemia virus p15E transmembrane protein in immunotherapy against AKR leukemia: a model for studies in human acquired immunodeficiency syndrome. 
  • Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. 
  • Role of the avian retrovirus mRNA leader in expression: evidence for novel translational control. 
  • Serologic Evidence of Fruit Bat Exposure to Filoviruses, Singapore, 2011-2016. 
  • Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. 
  • Similarity between p15E of murine and feline leukaemia viruses and p21 of HTLV. 
  • Single-round selection yields a unique retroviral envelope utilizing GPR172A as its host receptor. 
  • Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography. 
  • Specific association of retroviral envelope protein, p15E, with human cell surfaces. 
  • Sphingosine-1-phosphate phosphohydrolase regulates endoplasmic reticulum-to-golgi trafficking of ceramide. 
  • Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic. 
  • Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. 
  • Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. 
  • Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. 
  • Suppression of human interferon-gamma production by a 17 amino acid peptide homologous to the transmembrane envelope protein of retroviruses: evidence for a primary role played by monocytes. 
  • Suppression of the respiratory burst of human monocytes by a synthetic peptide homologous to envelope proteins of human and animal retroviruses. 
  • Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins. 
  • Telencephalic neurons monosynaptically link brainstem and forebrain premotor networks necessary for song. 
  • Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk. 
  • The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. 
  • The acidic domain of the hepatitis C virus NS4A protein is required for viral assembly and envelopment through interactions with the viral E1 glycoprotein. 
  • The effects of leukemosuppressive immunotherapy on bone marrow infectious cell centers in AKR mice. 
  • The erythropoietin receptor transmembrane region is necessary for activation by the Friend spleen focus-forming virus gp55 glycoprotein. 
  • The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors. 
  • The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly. 
  • The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. 
  • The promoter of human T-cell leukemia virus type-I is repressed by the immediate-early gene region of human cytomegalovirus in primary blood lymphocytes. 
  • The role of bone marrow and thymic elements in the initiation and spread of virus production in the AKR thymus. 
  • The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro. 
  • Therapeutic effects of diethylcarbamazine and 3'-azido-3'-deoxythymidine on feline leukemia virus lymphoma formation. 
  • Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. 
  • Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. 
  • Timing of retroviral infection influences anamnestic immune response in vaccinated primates. 
  • Transcriptional down-regulation of tumor necrosis factor-alpha gene expression by a synthetic peptide homologous to retroviral envelope protein. 
  • Transcriptional interference in avian retroviruses--implications for the promoter insertion model of leukaemogenesis. 
  • Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. 
  • Transmission of hepatitis B virus from an orthopedic surgeon with a high viral load. 
  • Transmitted/founder simian immunodeficiency virus envelope sequences in vesicular stomatitis and Semliki forest virus vector immunized rhesus macaques. 
  • Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. 
  • VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. 
  • Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. 
  • Viral induced fusion and syncytium formation: measurement by the Kolmogorov-Smirnov statistical test. 
  • Viral sequences determining the oncogenicity of avian leukosis viruses. 
  • Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. 
  • Visna virus encodes a post-transcriptional regulator of viral structural gene expression. 
  • Wild Mandrillus sphinx are carriers of two types of lentivirus. 
  • Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines? 
  • Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. 
  • [Antigenicity analysis of hemorrhagic fever with renal syndrome viruses by McAbs I]. 
  • [Characteristic analysis of E protein genes of new strains of tick-borne encephalitis virus isolated from China]. 
  • [Stimulation of immunoreactivity against endogenous retroviruses and protection against leukemia in aged AKR mice after vaccination with antibodies to viral surface components. The role of antibodies to p15(E)]. 
• 

  Keywords of People

  • Cianciolo, George James, Associate Professor in Pathology, Pathology
  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology
  • Luftig, Micah Alan, Associate Professor of Molecular Genetics and Microbiology, Immunology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, in the School of Medicine, Immunology